ImmuCell Corporation ICCC
10.26 USD +0.04 (+0.39%)
At closeNov 10, 2026, 4:00 PM EST
10.26 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
10.26 Day range 10.40
4.52 52-week range 12.10
- YTD
- +66.83%
- 1 year
- +68.75%
News
globenewswire.com ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026 Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET
zacks.com ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet? Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.
benzinga.com ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,
globenewswire.com ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets…
zacks.com ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2 ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
defenseworld.net ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell? ImmuCell Corporation (NASDAQ: ICCC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $8.64 and traded as…
seekingalpha.com ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
benzinga.com ImmuCell Reports Q2 2026 Results: Full Earnings Call Transcript ImmuCell (NASDAQ:ICCC) released second-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive…
marketbeat.com ImmuCell Q2 Earnings Call Highlights ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8…
benzinga.com ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.20 per share. This is a 233.33 percent increase over earnings of $0.06 per share from the same period last year. The company reported $7.186…
globenewswire.com ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets…
globenewswire.com ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026 PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets…
seekingalpha.com ImmuCell: First Defense With Better Execution ImmuCell's main value driver is First Defense. In my view, this is their core franchise and has real commercial momentum across year-round dairy customers. They've also shown improving manufacturing…
zacks.com ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand ICCC reports an 11.5% rise in preliminary Q2 sales, driven by robust U.S. demand and improved product availability, extending the momentum from its strong Q1 performance.
benzinga.com ImmuCell Q2 Total Product Sales Rises 12% ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,
globenewswire.com ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets…
zacks.com ICCC's Valuation Remains Premium: Is it Worth Overpaying for? ImmuCell's premium valuation is backed by rising output, First Defense share gains and a sizable untapped calf-health market opportunity.
zacks.com ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand ICCC posts record Q1 sales and 34% earnings growth as demand for its First Defense calf-health products boosts margins and market share.
marketbeat.com ImmuCell Q1 Earnings Call Highlights ImmuCell NASDAQ: ICCC reported a record first quarter of 2026, with management saying the company's narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever…
seekingalpha.com ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
benzinga.com ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoY ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.21 per share. This is a 31.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported $10.357…
globenewswire.com ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026 PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve…
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com ImmuCell And Norbrook Laboratories Reach Settlement Agreement, Norbrook To Pay $2M Following Expiration Of 2019 Supply Deal On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims…
globenewswire.com ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026 PORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve…
zacks.com The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell Goldman Sachs, NextEra Energy and Shopify lead top stock reports, highlighting strong gains, expanding operations and strategic shifts driving growth.
globenewswire.com ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve…- benzinga.com ImmuCell Reports Q1 Preliminary Sales $10.4M Up From 28.4% YoY ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today…
benzinga.com ImmuCell Q4 EPS $(0.31) Down From $0.06 YoY, Sales $7.626M Down From $7.751M YoY ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.31) per share. This is a 616.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $7.626…- benzinga.com Earnings Scheduled For March 4, 2026
- benzinga.com ImmuCell Reports Q4 Preliminary Net Sales Of $7.6M; Domestic Sales Were $7.0M In 2025, An 8.7% Increase Compared To 2024 ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today…
benzinga.com ImmuCell Pauses Re-Tain Drug After FDA Setback, Shifts Focus to Expanding First Defense Business ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it…
benzinga.com ImmuCell Puts Re-Tain On Pause After FDA Letter Animal health company ImmuCell receives an Incomplete Letter from the FDA for its Re-Tain NADA. Company shifts focus to First Defense.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com ImmuCell Has Decided To Pause Further Investment In Re-Tain In seeking FDA approval to bring its innovative Re-Tain® product to market, ImmuCell received Complete Letters from the FDA for four of the five Technical Sections required for NADA approval. It…
benzinga.com ImmuCell Increasing First Defense Field Sales Force By 50%, Expanding First Defense Production Capabilities After Receiving FDA's Incomplete Letter For Its Re-Tain New Animal Drug Application ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received…- benzinga.com ImmuCell Q3 EPS $(0.02) Up From $(0.09) YoY, Sales $5.506M Down From $6.012M YoY ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.02) per share. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported $5.506…
- benzinga.com Earnings Scheduled For November 13, 2025
benzinga.com ImmuCell Names Olivier te Boekhorst As President And CEO, Effective November 1, 2025, ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve…- benzinga.com ImmuCell Announces Preliminary Q3 2025 Revenue Of $5.5M ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve…
- benzinga.com ImmuCell Selects Olivier Te Boekhorst As Its Next President, CEO, Expected Start Date November 1, 2025 PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets…
- benzinga.com ImmuCell Q2 EPS $0.06 Up From $(0.20) YoY, Sales $6.445M Up From $5.473M YoY ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.06 per share. This is a 130 percent increase over losses of $(0.20) per share from the same period last year. The company reported $6.445…
- benzinga.com Earnings Scheduled For August 14, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For May 14, 2025
- benzinga.com ImmuCell Preliminary Q1 2025 Revenue Of $8.1M Up From $7.3M YoY; Reduced The Backlog Of Orders To $4M As Of March 31, 2025, From $4.4M As Of December 31, 2024 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve…
- benzinga.com ImmuCell Q4 EPS $0.06 Up From $(0.15) YoY, Sales $7.75M Up From $5.10M YoY ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.06 per share. This is a 140 percent increase over losses of $(0.15) per share from the same period last year. The company reported $7.75…
- benzinga.com Earnings Scheduled For February 25, 2025